Unique binding mode of Evogliptin with human dipeptidyl peptidase IV

Hyung Ki Lee, Mi Kyung Kim, Ha Dong Kim, Heung Jae Kim, Ji Won Kim, Jie Oh Lee, Chan Wha Kim, Eunice Eun Kyeong Kim

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Evogliptin ((R)-4-((R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl)-3-(tert-butoxymethyl) piperazine-2-one)) is a highly potent selective inhibitor of dipeptidyl peptidase IV (DPP4) that was approved for the treatment of type 2 diabetes in South Korea. In this study, we report the crystal structures of Evogliptin, DA-12166, and DA-12228 (S,R diastereomer of Evogliptin) complexed to human DPP4. Analysis of both the structures and inhibitory activities suggests that the binding of the trifluorophenyl moiety in the S1 pocket and the piperazine-2-one moiety have hydrophobic interactions with Phe357 in the S2 extensive subsite, and that the multiple hydrogen bonds made by the (R)-β-amine group in the S2 pocket and the contacts made by the (R)-tert-butyl group with Arg125 contribute to the high potency observed for Evogliptin.

Original languageEnglish
Pages (from-to)452-459
Number of pages8
JournalBiochemical and Biophysical Research Communications
Volume494
Issue number3-4
DOIs
Publication statusPublished - 2017 Dec 16

Fingerprint

Dipeptidyl Peptidase 4
Dipeptidyl-Peptidase IV Inhibitors
Republic of Korea
Medical problems
Hydrophobic and Hydrophilic Interactions
Type 2 Diabetes Mellitus
Amines
Hydrogen
Hydrogen bonds
Crystal structure
4-(3-amino-4-(2,4,5-trifluorophenyl)butanoyl)-3-(tert-butoxymethyl)piperazin-2-one
piperazine

Keywords

  • Complex structure
  • Diabetes
  • Dipeptidyl peptidase IV
  • DPP4
  • Evogliptin
  • Inhibitor

ASJC Scopus subject areas

  • Biophysics
  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Lee, H. K., Kim, M. K., Kim, H. D., Kim, H. J., Kim, J. W., Lee, J. O., ... Kim, E. E. K. (2017). Unique binding mode of Evogliptin with human dipeptidyl peptidase IV. Biochemical and Biophysical Research Communications, 494(3-4), 452-459. https://doi.org/10.1016/j.bbrc.2017.10.101

Unique binding mode of Evogliptin with human dipeptidyl peptidase IV. / Lee, Hyung Ki; Kim, Mi Kyung; Kim, Ha Dong; Kim, Heung Jae; Kim, Ji Won; Lee, Jie Oh; Kim, Chan Wha; Kim, Eunice Eun Kyeong.

In: Biochemical and Biophysical Research Communications, Vol. 494, No. 3-4, 16.12.2017, p. 452-459.

Research output: Contribution to journalArticle

Lee, Hyung Ki ; Kim, Mi Kyung ; Kim, Ha Dong ; Kim, Heung Jae ; Kim, Ji Won ; Lee, Jie Oh ; Kim, Chan Wha ; Kim, Eunice Eun Kyeong. / Unique binding mode of Evogliptin with human dipeptidyl peptidase IV. In: Biochemical and Biophysical Research Communications. 2017 ; Vol. 494, No. 3-4. pp. 452-459.
@article{de445b8678a349ddbb97500fade08584,
title = "Unique binding mode of Evogliptin with human dipeptidyl peptidase IV",
abstract = "Evogliptin ((R)-4-((R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl)-3-(tert-butoxymethyl) piperazine-2-one)) is a highly potent selective inhibitor of dipeptidyl peptidase IV (DPP4) that was approved for the treatment of type 2 diabetes in South Korea. In this study, we report the crystal structures of Evogliptin, DA-12166, and DA-12228 (S,R diastereomer of Evogliptin) complexed to human DPP4. Analysis of both the structures and inhibitory activities suggests that the binding of the trifluorophenyl moiety in the S1 pocket and the piperazine-2-one moiety have hydrophobic interactions with Phe357 in the S2 extensive subsite, and that the multiple hydrogen bonds made by the (R)-β-amine group in the S2 pocket and the contacts made by the (R)-tert-butyl group with Arg125 contribute to the high potency observed for Evogliptin.",
keywords = "Complex structure, Diabetes, Dipeptidyl peptidase IV, DPP4, Evogliptin, Inhibitor",
author = "Lee, {Hyung Ki} and Kim, {Mi Kyung} and Kim, {Ha Dong} and Kim, {Heung Jae} and Kim, {Ji Won} and Lee, {Jie Oh} and Kim, {Chan Wha} and Kim, {Eunice Eun Kyeong}",
year = "2017",
month = "12",
day = "16",
doi = "10.1016/j.bbrc.2017.10.101",
language = "English",
volume = "494",
pages = "452--459",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "3-4",

}

TY - JOUR

T1 - Unique binding mode of Evogliptin with human dipeptidyl peptidase IV

AU - Lee, Hyung Ki

AU - Kim, Mi Kyung

AU - Kim, Ha Dong

AU - Kim, Heung Jae

AU - Kim, Ji Won

AU - Lee, Jie Oh

AU - Kim, Chan Wha

AU - Kim, Eunice Eun Kyeong

PY - 2017/12/16

Y1 - 2017/12/16

N2 - Evogliptin ((R)-4-((R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl)-3-(tert-butoxymethyl) piperazine-2-one)) is a highly potent selective inhibitor of dipeptidyl peptidase IV (DPP4) that was approved for the treatment of type 2 diabetes in South Korea. In this study, we report the crystal structures of Evogliptin, DA-12166, and DA-12228 (S,R diastereomer of Evogliptin) complexed to human DPP4. Analysis of both the structures and inhibitory activities suggests that the binding of the trifluorophenyl moiety in the S1 pocket and the piperazine-2-one moiety have hydrophobic interactions with Phe357 in the S2 extensive subsite, and that the multiple hydrogen bonds made by the (R)-β-amine group in the S2 pocket and the contacts made by the (R)-tert-butyl group with Arg125 contribute to the high potency observed for Evogliptin.

AB - Evogliptin ((R)-4-((R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl)-3-(tert-butoxymethyl) piperazine-2-one)) is a highly potent selective inhibitor of dipeptidyl peptidase IV (DPP4) that was approved for the treatment of type 2 diabetes in South Korea. In this study, we report the crystal structures of Evogliptin, DA-12166, and DA-12228 (S,R diastereomer of Evogliptin) complexed to human DPP4. Analysis of both the structures and inhibitory activities suggests that the binding of the trifluorophenyl moiety in the S1 pocket and the piperazine-2-one moiety have hydrophobic interactions with Phe357 in the S2 extensive subsite, and that the multiple hydrogen bonds made by the (R)-β-amine group in the S2 pocket and the contacts made by the (R)-tert-butyl group with Arg125 contribute to the high potency observed for Evogliptin.

KW - Complex structure

KW - Diabetes

KW - Dipeptidyl peptidase IV

KW - DPP4

KW - Evogliptin

KW - Inhibitor

UR - http://www.scopus.com/inward/record.url?scp=85032980700&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032980700&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2017.10.101

DO - 10.1016/j.bbrc.2017.10.101

M3 - Article

C2 - 29061303

AN - SCOPUS:85032980700

VL - 494

SP - 452

EP - 459

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 3-4

ER -